Histone deacetylase inhibitors: understanding a new wave of anticancer agents - PubMed (original) (raw)

Review

. 2004 Nov 1;112(2):171-8.

doi: 10.1002/ijc.20372.

Affiliations

• PMID: 15352027
• DOI: 10.1002/ijc.20372

Review

Histone deacetylase inhibitors: understanding a new wave of anticancer agents

Ana Villar-Garea et al. Int J Cancer. 2004.

Abstract

Cancer is as much an epigenetic disease as it is a genetic and cytogenetic disease. The discovery that drastic changes in DNA methylation and histone modifications are commonly found in human tumors has inspired various laboratories and pharmaceutical companies to develop and study epigenetic drugs. One of the most promising groups of agents is the inhibitors of histone deacetylases (HDACs), which have different biochemical and biologic properties but have a single common activity: induction of acetylation in histones, the key proteins in nucleosome and chromatin structure. One of the main mechanisms of action of HDAC inhibitors is the transcriptional reactivation of dormant tumor-suppressor genes, such as p21WAF1. However, their pleiotropic nature leaves open the possibility that their well-known differentiation, cell-cycle arrest and apoptotic properties are also involved in other functions associated with HDAC inhibition. Many phase I clinical trials indicate that HDAC inhibitors appear to be well-tolerated drugs. Thus, the field is ready for rigorous biologic and clinical scrutiny to validate the therapeutic potential of these drugs. Our current data indicate that the use of HDAC inhibitors, probably in association with classical chemotherapy drugs or in combination with DNA-demethylating agents, could be promising for cancer patients.

Copyright 2004 Wiley-Liss, Inc.

PubMed Disclaimer

Similar articles

• CpG island methylation and histone modifications: biology and clinical significance.
  Esteller M. Esteller M. Ernst Schering Res Found Workshop. 2006;(57):115-26. doi: 10.1007/3-540-37633-x_7. Ernst Schering Res Found Workshop. 2006. PMID: 16568952 Review.
• Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis.
  Shankar S, Srivastava RK. Shankar S, et al. Adv Exp Med Biol. 2008;615:261-98. doi: 10.1007/978-1-4020-6554-5_13. Adv Exp Med Biol. 2008. PMID: 18437899 Review.
• Anticancer activities of histone deacetylase inhibitors.
  Bolden JE, Peart MJ, Johnstone RW. Bolden JE, et al. Nat Rev Drug Discov. 2006 Sep;5(9):769-84. doi: 10.1038/nrd2133. Nat Rev Drug Discov. 2006. PMID: 16955068 Review.
• Histone-deacetylase inhibitors: novel drugs for the treatment of cancer.
  Johnstone RW. Johnstone RW. Nat Rev Drug Discov. 2002 Apr;1(4):287-99. doi: 10.1038/nrd772. Nat Rev Drug Discov. 2002. PMID: 12120280 Review.
• Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
  Sigalotti L, Fratta E, Coral S, Cortini E, Covre A, Nicolay HJ, Anzalone L, Pezzani L, Di Giacomo AM, Fonsatti E, Colizzi F, Altomonte M, Calabrò L, Maio M. Sigalotti L, et al. J Cell Physiol. 2007 Aug;212(2):330-44. doi: 10.1002/jcp.21066. J Cell Physiol. 2007. PMID: 17458893 Review.

Cited by

• Valproic acid and bladder healing: an experimental study in rats.
  Biondo-Simões MLP, Dall'antonia MO, Goehr MP, Biondo-Simões R, Ioshii SO, Robes RR. Biondo-Simões MLP, et al. Rev Col Bras Cir. 2022 Nov 28;49:e20223399. doi: 10.1590/0100-6991e-20223399-en. eCollection 2022. Rev Col Bras Cir. 2022. PMID: 36449944 Free PMC article.
• Analysis of the genomic response of human prostate cancer cells to histone deacetylase inhibitors.
  Kortenhorst MS, Wissing MD, Rodríguez R, Kachhap SK, Jans JJ, Van der Groep P, Verheul HM, Gupta A, Aiyetan PO, van der Wall E, Carducci MA, Van Diest PJ, Marchionni L. Kortenhorst MS, et al. Epigenetics. 2013 Sep;8(9):907-20. doi: 10.4161/epi.25574. Epub 2013 Jul 19. Epigenetics. 2013. PMID: 23880963 Free PMC article.
• An active site tyrosine residue is essential for amidohydrolase but not for esterase activity of a class 2 histone deacetylase-like bacterial enzyme.
  Moreth K, Riester D, Hildmann C, Hempel R, Wegener D, Schober A, Schwienhorst A. Moreth K, et al. Biochem J. 2007 Feb 1;401(3):659-65. doi: 10.1042/BJ20061239. Biochem J. 2007. PMID: 17037985 Free PMC article.
• Butyrate mediates decrease of histone acetylation centered on transcription start sites and down-regulation of associated genes.
  Rada-Iglesias A, Enroth S, Ameur A, Koch CM, Clelland GK, Respuela-Alonso P, Wilcox S, Dovey OM, Ellis PD, Langford CF, Dunham I, Komorowski J, Wadelius C. Rada-Iglesias A, et al. Genome Res. 2007 Jun;17(6):708-19. doi: 10.1101/gr.5540007. Genome Res. 2007. PMID: 17567991 Free PMC article.
• Regulation of histone deacetylase 3 by metal cations and 10-hydroxy-2E-decenoic acid: Possible epigenetic mechanisms of queen-worker bee differentiation.
  Polsinelli GA, Yu HD. Polsinelli GA, et al. PLoS One. 2018 Dec 10;13(12):e0204538. doi: 10.1371/journal.pone.0204538. eCollection 2018. PLoS One. 2018. PMID: 30532259 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Wiley

• Other Literature Sources

  • The Lens - Patent Citations Database